bowang0911/MedQuAD huggingface dataset:
Tests that examine the lymph nodes are used to detect (find) and diagnose adult Hodgkin lymphoma. The following tests and procedures may be used:         -   Physical exam and history : An exam of the body to check general signs of health, including checking for signs of disease, such as lumps or anything else that seems unusual. A history of the patient's past illnesses and treatments will also be taken.    -   Complete blood count (CBC): A procedure in which a sample of blood is drawn and checked for the following:                - The number of red blood cells, white blood cells, and platelets.      - The amount of hemoglobin (the protein that carries oxygen) in the red blood cells.      - The portion of the sample made up of red blood cells.             -   Blood chemistry studies : A procedure in which a blood sample is checked to measure the amounts of certain substances released into the blood by organs and tissues in the body. An unusual (higher or lower than normal) amount of a substance can be a sign of disease.    -   Sedimentation rate : A procedure in which a sample of blood is drawn and checked for the rate at which the red blood cells settle to the bottom of the test tube. The sedimentation rate is a measure of how much inflammation is in the body. A higher than normal sedimentation rate may be a sign of lymphoma or another condition. Also called erythrocyte sedimentation rate, sed rate, or ESR.    -  Lymph node biopsy : The removal of all or part of a lymph node. One of the following types of biopsies may be done:                -  Excisional biopsy : The removal of an entire lymph node.       -  Incisional biopsy : The removal of part of a lymph node.      -  Core biopsy : The removal of part of a lymph node using a wide needle.          A pathologist views the tissue under a microscope to look for cancer cells, especially Reed-Sternberg cells. Reed-Sternberg cells are common in classical Hodgkin lymphoma.  The following test may be done on tissue that was removed:               -  Immunophenotyping : A laboratory test used to identify cells, based on the types of antigens or markers on the surface of the cell. This test is used to diagnose the specific type of lymphoma by comparing the cancer cells to normal cells of the immune system.
Certain factors affect prognosis (chance of recovery) and treatment options. The prognosis (chance of recovery) and treatment options depend on the following:         - The patient's signs and symptoms.    - The stage of the cancer.    - The type of Hodgkin lymphoma.    -  Blood test results.    - The patient's age, gender, and general health.    - Whether the cancer is recurrent or progressive.        For Hodgkin lymphoma during pregnancy, treatment options also depend on:         - The wishes of the patient.    - The age of the fetus.        Adult Hodgkin lymphoma can usually be cured if found and treated early.
New types of treatment are being tested in clinical trials.
                    This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.     Chemotherapy and radiation therapy with stem cell transplant     High-dose chemotherapy and radiation therapy with stem cell transplant is a way of giving high doses of chemotherapy and radiation therapy and replacing blood -forming cells destroyed by the cancer treatment. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After therapy is completed, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells. The use of lower-dose chemotherapy and radiation therapy with stem cell transplant is also being studied.       Monoclonal antibody therapy      Monoclonal antibody therapy is a cancer treatment that uses antibodies made in the laboratory, from a single type of immune system cell. These antibodies can identify substances on cancer cells or normal substances that may help cancer cells grow. The antibodies attach to the substances and kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.
                 
                
                    Patients may want to think about taking part in a clinical trial.
                    For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.   Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.   Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
                
                
                    Patients can enter clinical trials before, during, or after starting their cancer treatment.
                    Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.   Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.
Key Points
                    - Bile duct cancer is a rare disease in which malignant (cancer) cells form in the bile ducts.     - Having colitis or certain liver diseases can increase the risk of bile duct cancer.    - Signs of bile duct cancer include jaundice and pain in the abdomen.    - Tests that examine the bile ducts and nearby organs are used to detect (find), diagnose, and stage bile duct cancer.    - Different procedures may be used to obtain a sample of tissue and diagnose bile duct cancer.     - Certain factors affect prognosis (chance of recovery) and treatment options.
                
                
                    Bile duct cancer is a rare disease in which malignant (cancer) cells form in the bile ducts.
                    A network of tubes, called ducts, connects the liver, gallbladder, and small intestine. This network begins in the liver where many small ducts collect bile (a fluid made by the liver to break down fats during digestion). The small ducts come together to form the right and left hepatic ducts, which lead out of the liver. The two ducts join outside the liver and form the common hepatic duct. The cystic duct connects the gallbladder to the common hepatic duct. Bile from the liver passes through the hepatic ducts, common hepatic duct, and cystic duct and is stored in the gallbladder.    When food is being digested, bile stored in the gallbladder is released and passes through the cystic duct to the common bile duct and into the small intestine.    Bile duct cancer is also called cholangiocarcinoma.   There are two types of bile duct cancer:         -   Intrahepatic bile duct cancer : This type of cancer forms in the bile ducts inside the liver. Only a small number of bile duct cancers are intrahepatic. Intrahepatic bile duct cancers are also called intrahepatic cholangiocarcinomas.    -   Extrahepatic bile duct cancer : The extrahepatic bile duct is made up of the hilum region and the distal region. Cancer can form in either region:                - Perihilar bile duct cancer: This type of cancer is found in the hilum region, the area where the right and left bile ducts exit the liver and join to form the common hepatic duct. Perihilar bile duct cancer is also called a Klatskin tumor or perihilar cholangiocarcinoma.      - Distal extrahepatic bile duct cancer: This type of cancer is found in the distal region. The distal region is made up of the common bile duct which passes through the pancreas and ends in the small intestine. Distal extrahepatic bile duct cancer is also called extrahepatic cholangiocarcinoma.
Having colitis or certain liver diseases can increase the risk of bile duct cancer. Anything that increases your risk of getting a disease is called a risk factor. Having a risk factor does not mean that you will get cancer; not having risk factors doesn't mean that you will not get cancer. People who think they may be at risk should discuss this with their doctor.    Risk factors for bile duct cancer include the following conditions:         - Primary sclerosing cholangitis (a progressive disease in which the bile ducts become blocked by inflammation and scarring).    -  Chronic ulcerative colitis.    -  Cysts in the bile ducts (cysts block the flow of bile and can cause swollen bile ducts, inflammation, and infection).    - Infection with a Chinese liver fluke parasite.
Signs of bile duct cancer include jaundice and pain in the abdomen. These and other signs and symptoms may be caused by bile duct cancer or by other conditions. Check with your doctor if you have any of the following:         -  Jaundice (yellowing of the skin or whites of the eyes).    - Dark urine.    - Clay colored stool.    - Pain in the abdomen.    -  Fever.    - Itchy skin.    -  Nausea and vomiting.    - Weight loss for an unknown reason.
Certain factors affect prognosis (chance of recovery) and treatment options. The prognosis (chance of recovery) and treatment options depend on the following:         - Whether the cancer is in the upper or lower part of the bile duct system.     - The stage of the cancer (whether it affects only the bile ducts or has spread to the liver, lymph nodes, or other places in the body).    - Whether the cancer has spread to nearby nerves or veins.    - Whether the cancer can be completely removed by surgery.    - Whether the patient has other conditions, such as primary sclerosing cholangitis.    - Whether the level of CA 19-9 is higher than normal.    - Whether the cancer has just been diagnosed or has recurred (come back).        Treatment options may also depend on the symptoms caused by the cancer. Bile duct cancer is usually found after it has spread and can rarely be completely removed by surgery. Palliative therapy may relieve symptoms and improve the patient's quality of life.
New types of treatment are being tested in clinical trials.
                    This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.     Liver transplant    In a liver transplant, the entire liver is removed and replaced with a healthy donated liver. A liver transplant may be done in patients with perihilar bile duct cancer. If the patient has to wait for a donated liver, other treatment is given as needed.
                
                
                    Patients may want to think about taking part in a clinical trial.
                    For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.   Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.   Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
                
                
                    Patients can enter clinical trials before, during, or after starting their cancer treatment.
                    Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.   Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.
Key Points
                    - Intraocular melanoma is a disease in which malignant (cancer) cells form in the tissues of the eye.    - Being older and having fair skin may increase the risk of intraocular melanoma.    - Signs of intraocular melanoma include blurred vision or a dark spot on the iris.     - Tests that examine the eye are used to help detect (find) and diagnose intraocular melanoma.    - A biopsy of the tumor is rarely needed to diagnose intraocular melanoma.    - Certain factors affect prognosis (chance of recovery) and treatment options.
                
                
                    Intraocular melanoma is a disease in which malignant (cancer) cells form in the tissues of the eye.
                    Intraocular melanoma begins in the middle of three layers of the wall of the eye. The outer layer includes the white sclera (the "white of the eye") and the clear cornea at the front of the eye. The inner layer has a lining of nerve tissue, called the retina, which senses light and sends images along the optic nerve to the brain.   The middle layer, where intraocular melanoma forms, is called the uvea or uveal tract, and has three main parts:         -  Iris  The iris is the colored area at the front of the eye (the "eye color"). It can be seen through the clear cornea. The pupil is in the center of the iris and it changes size to let more or less light into the eye. Intraocular melanoma of the iris is usually a small tumor that grows slowly and rarely spreads to other parts of the body.    -  Ciliary body  The ciliary body is a ring of tissue with muscle fibers that change the size of the pupil and the shape of the lens. It is found behind the iris. Changes in the shape of the lens help the eye focus. The ciliary body also makes the clear fluid that fills the space between the cornea and the iris. Intraocular melanoma of the ciliary body is often larger and more likely to spread to other parts of the body than intraocular melanoma of the iris.      -  Choroid  The choroid is a layer of blood vessels that bring oxygen and nutrients to the eye. Most intraocular melanomas begin in the choroid. Intraocular melanoma of the choroid is often larger and more likely to spread to other parts of the body than intraocular melanoma of the iris.          Intraocular melanoma is a rare cancer that forms from cells that make melanin in the iris, ciliary body, and choroid. It is the most common eye cancer in adults.
Being older and having fair skin may increase the risk of intraocular melanoma. Anything that increases your risk of getting a disease is called a risk factor. Having a risk factor does not mean that you will get cancer; not having risk factors doesnt mean that you will not get cancer. Talk with your doctor if you think you may be at risk.    Risk factors for intraocular melanoma include the following:         - Having a fair complexion, which includes the following:                - Fair skin that freckles and burns easily, does not tan, or tans poorly.      - Blue or green or other light-colored eyes.             - Older age.    - Being white.
Signs of intraocular melanoma include blurred vision or a dark spot on the iris. Intraocular melanoma may not cause early signs or symptoms. It is sometimes found during a regular eye exam when the doctor dilates the pupil and looks into the eye. Signs and symptoms may be caused by intraocular melanoma or by other conditions. Check with your doctor if you have any of the following:         - Blurred vision or other change in vision.    - Floaters (spots that drift in your field of vision) or flashes of light.    - A dark spot on the iris.    - A change in the size or shape of the pupil.    - A change in the position of the eyeball in the eye socket.
Certain factors affect prognosis (chance of recovery) and treatment options. The prognosis (chance of recovery) and treatment options depend on the following:          - How the melanoma cells look under a microscope.    - The size and thickness of the tumor.    - The part of the eye the tumor is in (the iris, ciliary body, or choroid).    - Whether the tumor has spread within the eye or to other places in the body.    - Whether there are certain changes in the genes linked to intraocular melanoma.    - The patient's age and general health.    - Whether the tumor has recurred (come back) after treatment.
Smoking is the major risk factor for non-small cell lung cancer. Anything that increases your chance of getting a disease is called a risk factor. Having a risk factor does not mean that you will get cancer; not having risk factors doesn't mean that you will not get cancer. Talk to your doctor if you think you may be at risk for lung cancer.    Risk factors for lung cancer include the following:            -  Smoking cigarettes, pipes, or cigars, now or in the past. This is the most important risk factor for lung cancer. The earlier in life a person starts smoking, the more often a person smokes, and the more years a person smokes, the greater the risk of lung cancer.      -  Being exposed to secondhand smoke.     - Being exposed to radiation from any of the following:                  -  Radiation therapy to the breast or chest.       -  Radon in the home or workplace.       -  Imaging tests such as CT scans.       - Atomic bomb radiation.                 -  Being exposed to asbestos, chromium, nickel, beryllium, arsenic, soot, or tar in the workplace.     -  Living where there is air pollution.     -  Having a family history of lung cancer.     -  Being infected with the human immunodeficiency virus (HIV).     -  Taking beta carotene supplements and being a heavy smoker.           Older age is the main risk factor for most cancers. The chance of getting cancer increases as you get older.     When smoking is combined with other risk factors, the risk of lung cancer is increased.
Signs of non-small cell lung cancer include a cough that doesn't go away and shortness of breath. Sometimes lung cancer does not cause any signs or symptoms. It may be found during a chest x-ray done for another condition. Signs and symptoms may be caused by lung cancer or by other conditions. Check with your doctor if you have any of the following:         - Chest discomfort or pain.    - A cough that doesnt go away or gets worse over time.     - Trouble breathing.     - Wheezing.     -  Blood in sputum (mucus coughed up from the lungs).     - Hoarseness.     - Loss of appetite.    - Weight loss for no known reason.     - Feeling very tired.    - Trouble swallowing.    - Swelling in the face and/or veins in the neck.
Certain factors affect prognosis (chance of recovery) and treatment options. The prognosis (chance of recovery) and treatment options depend on the following:         - The stage of the cancer (the size of the tumor and whether it is in the lung only or has spread to other places in the body).    - The type of lung cancer.    - Whether the cancer has mutations (changes) in certain genes, such as the epidermal growth factor receptor (EGFR) gene or the anaplastic lymphoma kinase (ALK) gene.    - Whether there are signs and symptoms such as coughing or trouble breathing.    - The patients general health.
New types of treatment are being tested in clinical trials.
                    This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.     Chemoprevention     Chemoprevention is the use of drugs, vitamins, or other substances to reduce the risk of cancer or to reduce the risk cancer will recur (come back). For lung cancer, chemoprevention is used to lessen the chance that a new tumor will form in the lung.       Radiosensitizers     Radiosensitizers are substances that make tumor cells easier to kill with radiation therapy. The combination of chemotherapy and radiation therapy given with a radiosensitizer is being studied in the treatment of non-small cell lung cancer.       New combinations    New combinations of treatments are being studied in clinical trials.
                
                
                    Patients may want to think about taking part in a clinical trial.
                    For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.   Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.   Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
                
                
                    Patients can enter clinical trials before, during, or after starting their cancer treatment.
                    Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.   Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.
Key Points
                    - Ovarian low malignant potential tumor is a disease in which abnormal cells form in the tissue covering the ovary.     - Signs and symptoms of ovarian low malignant potential tumor include pain or swelling in the abdomen.    - Tests that examine the ovaries are used to detect (find), diagnose, and stage ovarian low malignant potential tumor.    - Certain factors affect prognosis (chance of recovery) and treatment options.
                
                
                    Ovarian low malignant potential tumor is a disease in which abnormal cells form in the tissue covering the ovary.
                    Ovarian low malignant potential tumors have abnormal cells that may become cancer, but usually do not. This disease usually remains in the ovary. When disease is found in one ovary, the other ovary should also be checked carefully for signs of disease.    The ovaries are a pair of organs in the female reproductive system. They are in the pelvis, one on each side of the uterus (the hollow, pear-shaped organ where a fetus grows). Each ovary is about the size and shape of an almond. The ovaries make eggs and female hormones.
Signs and symptoms of ovarian low malignant potential tumor include pain or swelling in the abdomen.Ovarian low malignant potential tumor may not cause early signs or symptoms. If you do have signs or symptoms, they may include the following:         - Pain or swelling in the abdomen.    - Pain in the pelvis.    -  Gastrointestinal problems, such as gas, bloating, or constipation.        These signs and symptoms may be caused by other conditions. If they get worse or do not go away on their own, check with your doctor.